Interactions between inhibitors of the proteasome and histone deacetylases have been examined in human T-leukemia/ lymphoma cells both in vitro and in vivo. Co-exposure of cells to bortezomib and suberoylanilide hydroxamic acid (SAHA) synergistically induces T-leukemia/lymphoma cells to undergo apoptosis, consistent with a significant increase in mitochondrial injury and caspase activation. These events are accompanied by inhibition of cyto-protective signaling pathways, including the nuclear factor (NF)-jB, Raf-1/mitogen-induced extracellular kinase (MEK)/extracellular signal-related kinase (ERK) and AKT pathways, and activation of stress-related cascades, including the stress-activated kinases c-jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38MAPK). Moreover, bortezomib in conjunction with SAHA efficiently induces apoptosis of primary T-leukemia/lymphoma cells and inhibits tumor growth in a murine xenograft model established with subcutaneous injection of Jurkat cells. Taken together, these findings confirm the synergistic anti-tumor effect of the proteasome and histone deacetylase inhibitors, and provide an insight into the future clinical applications of bortezomib-SAHA combining regimen in treating T-cell malignancies.
Introduction
T-cell acute lymphoblastic leukemia and T-cell lymphoma are usually aggressive tumors. Although conventional chemotherapy induces a high rate of complete remission, relapse is frequently observed, and these patients eventually present poor clinical outcome. 1, 2 Insights into the pathogenesis of T-cell malignancies have recently emerged, including alternations in cell proliferation and apoptosis, and the dysregulations of multiple intracellular signaling pathways, such as nuclear factor (NF)-kB, 3 ,4 extracellular signal-regulating kinase 1/2 (ERK1/2), 5, 6 AKT, 5, 7 c-jun N-terminal kinase (JNK) 8 and p38 mitogenactivated protein kinase (p38MAPK). 9 Therefore, new regimens need to be investigated, particularly those non-chemotherapeutic agents that specifically target pathways on which malignant T cells depend for their survival.
Proteasome inhibitors represent a new treatment strategy targeting the 26S proteasome, a component of the ubiquitinproteasome complex responsible for the degradation of unwanted cellular proteins. These inhibitors show significant activity against various cancer cells, leading to the induction of cellular apoptosis. 10 Bortezomib (Velcade, PS-341) is the first clinically available proteasome inhibitor and its use has recently been reported in the treatment of T-cell lymphoma. 11, 12 Histone deacetylase inhibitors (HDACIs) constitute a group of compounds that promote histone acetylation, chromatin uncoiling and transcription of genes involved in multiple cellular processes, including apoptosis. 13 Suberoylanilide hydroxamic acid (SAHA), a hydroxamic acid HDACI, has shown singleagent efficacy on cutaneous T-cell lymphoma. 14 Earlier studies have shown that inhibition of both the proteasome and histone deacetylase (HDAC) cooperatively functions against B-cell malignancies, such as multiple myeloma, mantle cell lymphoma and chronic lymphocytic leukemia. [15] [16] [17] However, the possible effects and therapeutic mechanism of this combination in T-cell malignancies remain to be defined. To address this issue, we examined the combinatorial action of the proteasome inhibitor bortezomib with the HDACI-SAHA in T-leukemia/lymphoma cells both in vitro and in vivo. These two agents interact in a highly synergistic manner to induce apoptosis in T-leukemia/ lymphoma cells, which are associated with multiple perturbations in apoptotic and survival pathways. Moreover, the bortezomib-SAHA combining regimen potently reduces the tumor size and induces tumor cell apoptosis in situ in a murine xenograft model. Therefore, an approach combining a clinically relevant proteasome inhibitor with HDACI warrants further investigation as a therapeutic strategy for T-cell malignancies.
Materials and methods

Cells and reagents
T-leukemia (Jurkat and MOLT-4) and lymphoma (HUT78, H9 and HUT102) cell lines were obtained from the American Type Culture Collection (Bethesda, MD, USA). The T-leukemia cell line 6T-CEM was from Cell Resource Center of Shanghai Institute of Biological Sciences (Shanghai, China). Cells were maintained in RPMI-1640 medium, supplemented with 10% heat-inactivated fetal bovine serum in a humidified atmosphere of 95% air and 5% CO 2 at 37 1C. Cell viability was estimated by trypan blue dye exclusion. Cell morphology was evaluated by Wright's staining under light microscopy.
Fresh leukemia cells from the bone marrow of two T-cell leukemia patients were enriched by Ficoll separation, and lymphoma cells from the lymph node of two T-cell lymphoma cases were also obtained. Normal T-lymphocytes were purified from human peripheral blood using Pan T Cell Isolation Kit II (Miltenyi Biotec Inc., Auburn, CA, USA). CD34 þ cells were obtained from human cord blood or peripheral stem cells collection products, using CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec Inc. 
and chemiluminescence phototope-horseradish peroxidase kit were obtained from Cell Signaling (Beverly, MA, USA). Specific inhibitor of JNK (SP600125) and p38MAPK (SB203580) were purchased from Calbiochem (La Jolla, CA, USA). Anti-acetylated lysine antibody was obtained from Upstate Biotech (Lake Placid, NY, USA).
Cell apoptosis assays and mitochondrial trans-membrane potentials (DCm)
Cell apoptosis was evaluated using ApoAlert Annexin-V-FITC Apoptosis Kit (Clontech Laboratories Inc., Palo Alto, CA, USA). For DCm, cells were incubated with 10 mg/ml Rh123 for 30 min at 37 1C and stained with 50 mg/ml propidium iodide. The fluorescent intensity was measured by flow cytometry. All assays were set up in triplicate.
Isobolographic analysis for determination of synergy
Determination of the synergistic versus additive versus antagonistic inhibitory effects of bortezomib and SAHA combination was made using the isobologram of Steel and Peckham. 18 On the basis of dose-response curves of the two drugs, three isoeffect curves were constructed. The area surrounded by the isoeffect curves was referred as the envelope of additivity. When the data points of the drug combination fell within the envelope, the combination was regarded as additive. When the data points fell to the left of the envelope, that is, the combined effect was caused by lower doses of the two agents than was predicted, the combination was regarded as having a supra-additive (synergistic) effect.
Terminal deoxytransferase-catalyzed DNA nick-end labeling (TUNEL) assay
In situ cell apoptosis was confirmed by detection of fragmented DNA, using TUNEL assay, 19 on deparaffinized 5-mm-thick tumor sections. For quantification, three different fields were counted under light microscopy and at least 500 cells were enumerated in each field. All experiments were performed in duplicate.
Nuclear fractionation
Cells were incubated in 400 ml lysis buffer (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM DTT, pH 7.9) with 0.2% Nonidet P-40 and protease inhibitor cocktail for 10 min on ice. After spinning at 2500 g for 1 min at 4 1C, cell pellets were washed with lysis buffer without Nonidet P-40, re-suspended in 150 ml extraction buffer (20 mM HEPES, pH 7.9, 420 mM NaCl, 0.5 mM DTT, 0.2 mM EDTA, 25% glycerol) for 10 min on ice, vortexed and centrifuged at 12 000 g for 10 min at 4 1C. The supernatants were collected as nuclear protein extracts.
Western blot
Cells were lysed in 200 ml lysis buffer (0.5 M Tris-HCl, pH 6.8, 2 mM EDTA, 10% glycerol, 2% SDS, 5% b-mercaptoethanol) or Radio Immunoprecipitation Assay (RIPA) lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS). Protein extracts (20 mg) were loaded onto a 10% polyacrylamide gel containing SDS, electrophoresed and transferred to a nitrocellulose membrane. The membranes were blocked with 5% non-fat dried milk in Tris-buffered saline/0.1% Tween 20 and incubated for 2 h at room temperature with the appropriate primary antibody, followed by treatment with horseradish peroxidase-linked secondary antibody. The immunocomplexes were visualized using a chemiluminescence phototope-horseradish peroxidase kit. Lamin B and GAPDH were used to ensure equivalent loading of nuclear and whole cell protein, respectively. Acetylated histones were detected using the anti-acetylated lysine antibody, and 15% polyacrylamide gels were run in parallel and stained with Coomassie blue as histone loading control. 20 All the data were confirmed by three individual experiments.
Murine model
Nude mice (5-6 weeks old) were obtained from the Shanghai Laboratory Animal Center (Shanghai, China) and injected subcutaneously with 4 Â 10 7 Jurkat cells into the right flank (day 0). Treatments (10 mice per group) were started 21 days after Jurkat cell injections. The control group received dimethyl sulfoxide (DMSO), while the other three groups received intraperitoneal bortezomib (60 mg/kg every day for 14 days), SAHA (50 mg/kg every day for 14 days) or the combination treatment, respectively. Tumor volumes were measured daily and calculated using the formula 0.5 Â a Â b 2 in millimeters, where 'a' is the length and 'b' is the width. Tissue samples were fixed in formaldehyde and further processed for paraffin embedding.
Statistical analysis
Variance between the treatment groups was measured using a two-tailed t-test. Po0.05 was considered to be significant. All statistical analyses were performed on SAS 8.2 software (SAS Institute Inc., Cary, NC, USA).
Results
Combination of the proteasome inhibitor bortezomib with the HDACI SAHA induces synergistic cytotoxicity in T-leukemia/lymphoma cells
The leukemia cell line Jurkat and the lymphoma cell line HUT78 were treated with different concentrations of bortezomib and/or SAHA for 48 h. Dose-response curves are shown in Figure 1a . Compared with each agent alone, a marked decrease in cell survival rate is observed with combined treatment. For example, 10 nM bortezomib and 2 mM SAHA alone induce approximately 40-50% reduction in cell viability; however, in combination they achieve more than an 80% cell reduction. Isobolographic analysis yields most of the data points to the left of the envelope of additivity, denoting highly synergistic interactions in both cell lines (Figure 1b) . Similar results are obtained with other T-leukemia (MOLT-4 and 6T-CEM) or lymphoma cell lines (H9 and HUT102) (Figure 1c ).
Bortezomib combined with SAHA triggers apoptosis through mitochondrial injury and caspase activation
Morphologically enhanced cellular apoptosis is detected after 24 h of co-exposure, and increases substantially at 48 h (Figure 2a) . Flow-cytometric analysis confirms that rapid induction of cell apoptosis occurs following the combination treatment (representative results shown in Figure 2b , upper panel). After 24 h, the percentage of Annexin V þ cells increases to 35.2% in Jurkat and 48.6% in HUT78 cells, which are significantly higher than the percentages of those treated with bortezomib (7.6 and 7.3%) or SAHA alone (9.9 and 7.4%).
Marked dissipation of DCm, as represented by the cells with decreased Rh123 fluorescence, is also observed in both cell lines co-treated with bortezomib and SAHA at 24 h (37.0 and 56.9%), compared with those treated with bortezomib (11.5 and 13.4%) or SAHA alone (12.7 and 14.3%) (representative results shown in Figure 2b, lower panel) .
Western blot analysis shows that bortezomib in combination with SAHA significantly induces cleavage of caspase-8, -9 and -3, whereas single treatment exerts minimal effects (Figure 2c) . Therefore, bortezomib in conjunction with SAHA represents a potent stimulus for mitochondrial dysfunction and caspase activation in T-leukemia/lymphoma cells.
Effects of bortezomib-SAHA combination involve multiple signaling pathways: signaling is re-directed away from cyto-protective and toward stress-related cascades To gain insight into the molecular mechanisms involved in combination treatment, several signaling pathways linking to cell proliferation and apoptosis were investigated.
NF-kB is rendered inactive within the cell cytoplasm by IkB inhibitors, mainly IkBa. IkBa is regulated by the IkB kinase (IKK) complex, which consists of the kinase catalytic subunits IKKa/b. 21 As shown in Figure 3a , nuclear NF-kB is particularly reduced after co-treatment with bortezomib and SAHA. In whole cells, the phosphorylation-dependent state of IKKa is significantly decreased in the combination group, whereas its basal level (phosphorylation-independent state) remains unchanged.
Although bortezomib and SAHA alone have little effect on the Raf-1/MEK/ERK pathway, cells exposed to a combination of the two drugs exhibit reduced expression of Raf-1, MEKK-1 and MEKK-2. Consequently, phosphorylation of MEK and ERK is decreased without obvious changes in total MEK and ERK levels (Figure 3b) . The same profile is observed for AKT expression; combined treatment of bortezomib with SAHA induces a reduction in the phosphorylated form of AKT. AKT itself is also reduced in Jurkat cells (Figure 3c ).
The effects of bortezomib and SAHA were examined in relation to the perturbations of stress-related signaling modules (Figure 3d ). Whereas each of the agents administered individually exert a mild effect on JNK levels, combined treatment markedly augments both JNK phosphorylation and total JNK. Moreover, whereas bortezomib or SAHA alone modestly activates p38MAPK, co-administration of bortezomib and SAHA results in a marked increase in phosphorylation of p38MAPK. Addition of JNK inhibitor or p38MAPK inhibitor results in significantly fewer apoptotic cells compared with treatment with bortezomib/SAHA combination (Po0.05) (Figure 3e) .
Finally, studies were undertaken to determine whether the combined effect of bortezomib and SAHA might be related to histone acetylation. As shown in Figure 3f , synergistic apoptosis induced by bortezomib and SAHA seems to be independent of histone H3/H4 acetylation.
Combination of bortezomib with SAHA induces primary T-leukemia/lymphoma cells apoptosis and inhibits tumor growth in a murine xenograft model
Combined treatment with 10 nM bortezomib and 2 mM SAHA significantly inhibits cell growth and results in 480% cell inhibition in primary T-leukemia/lymphoma cells (Figure 4a ). Typical morphological changes of apoptosis were also observed (Figure 4b ). However, proliferation of normal T lymphocytes isolated from human peripheral blood (n ¼ 3), and CD34 þ cells from human cord blood (n ¼ 3) or peripheral stem cells collection products (n ¼ 3) was not affected at concentrations up to 25 nM bortezomib combined with 4 mM SAHA (Figures 4c-e) .
The in vivo anti-tumor activity of bortezomib and SAHA on T-leukemia/lymphoma cells was further evaluated in a murine xenograft model. Of the cell lines tested, only the subcutaneous inoculation of Jurkat cells into nude mice resulted in a tumor formation at the site of injection in all mice (Figure 4f ). The sizes of tumors formed in mice co-treated with bortezomib and SAHA were significantly smaller than those of the control and singletreatment groups after 11 days of treatment (Po0.0001) (Figure 4g ).
To search for more evidence of tumor cell apoptosis, a TUNEL assay was performed on mice tumor sections. Compared with the control and single-treatment groups, the number of apoptotic tumor cells was increased following combined treatment with bortezomib and SAHA (Figures 4h and i) . 
Discussion
This study shows the activity of the clinically relevant proteasome inhibitor bortezomib combined with HDACI SAHA against T-cell leukemia/lymphoma both in vitro and in vivo. The observed synergy in cytotoxicity, accomplished by the combination of the above inhibitors, seems to result from the convergent effect on cell apoptosis mediated by mitochondrial dysfunction and caspase activation.
Multiple potential molecular mechanisms may contribute to the synergy between bortezomib and SAHA in T-leukemia/ lymphoma cells. Cyto-protective pathways, such as NF-kB, ERK and AKT, confer a survival advantage on malignant T-lymphocytes, not only protecting the cells from apoptosis but also rendering them resistant to conventional cytotoxic drugs. The NF-kB pathway is one of the most important signaling cascades that promote the expression of proliferative and anti-apoptotic genes. Bortezomib prevents NF-kB nuclear translocation and subsequent transactivation, which could lower the threshold for HDACI lethality. 22 Recent studies have confirmed that bortezomib sensitizes B-lymphoma cells to HDACI-mediated apoptosis through inhibition of the NF-kB pathway. 16, 17 In this study, when bortezomib was used in combination with SAHA, a significant decrease in the phosphorylation-dependent state of IKKa/b was observed concomitant to the blockade of NF-kB nuclear translocation, suggestive of their synergic mechanism as negative regulators of the NF-kB pathway.
The Raf-1/MEK/ERK pathway is also involved in the control of hematopoietic cell proliferation, and its interruption precedes pro-apoptotic signals. 23 Specific blockade of this pathway by bortezomib synergistically potentiates HDACI-induced apoptosis of myeloid leukemia cells. 24, 25 In addition to inactivation of NF-kB, bortezomib and SAHA together could inhibit the upstream regulators of ERK pathway, such as Raf-1, MEKK-1 and MEKK-2 in T-leukemia/lymphoma cells, resulting in downregulation of MEK and ERK phosphorylation. These findings further underline the functional complementation of both agents in the inhibition of the ERK pathway.
Finally, bortezomib and SAHA individually abrogate the expression of cyto-protective AKT. 26, 27 Our data show that the combination of bortezomib and SAHA attenuates the levels of the phosphorylated form of AKT and/or total AKT, indicating an additional role in AKT signaling to further down-modulate the apoptotic threshold. It is of interest that cross-talk between the ERK and AKT cascades has been recently described. 28 Thus, in T-cell leukemia/lymphoma, combined downregulation of ERK and AKT may be considerably more lethal than interruption of either pathway alone.
Similar to ERK, JNK and p38MAPK are members of the MAPK pathways and are implicated in the control of cellular survival and stress responses. However, differences exist; ERK activation Cell apoptosis induced by bortizomib and SAHA is significantly reduced by co-treatment with the JNK inhibitor SP600125 or the p38MAPK inhibitor SB203580 (e). However, no additive effect on levels of histones H3 and H4 is found in the combination group (f). is generally associated with enhanced cell survival, whereas JNK and p38MAPK are related to cell death. Particularly, a recent study showed the role of p38 MAPK as a tumor suppressor. 29 This involves promoting cell growth arrest and inducing cell apoptosis. 30 Bortezomib-mediated induction of apoptosis in leukemia cells has been linked to JNK and p38MAPK activation. 31 Upregulation of stress-related cascades is also one of the important factors involved in SAHA-mediated lethality. 32 In this study, when bortezomib was combined with SAHA, significant increase of the JNK and p38MARK was observed and both inhibitors attenuated T-leukemia/lymphoma cell apoptosis, indicating their synergic effect on stress-related cell apoptosis cascades.
Collectively, the net balance between cyto-protective pathways and stress-related cascades is known to be a critical determinant of cell fate. Bortezomib may interact with SAHA by disrupting multiple cyto-protective signaling pathways and by shifting the balance toward their stress-related counterparts, which trigger mitochondrial damage, caspase activation and eventually lead to irreversible engagement of the apoptotic cascade in T-leukemia/lymphoma cells. Such findings are in accord with the report by Yu et al., 33 which earlier described the synergistic induction of apoptosis in Bcr-abl þ cells exposed to a proteasome inhibitor in combination with HDACI.
In conclusion, molecular targeting of HDAC and the proteasome in combination synergistically induces apoptosis in T-leukemia/lymphoma cells, providing a promising rationale for this combination regimen in treating patients with T-cell malignancies.
